PureTech Health PLC Director/PDMR Shareholding
27 Junio 2024 - 11:00AM
RNS Regulatory News
RNS Number : 2103U
PureTech Health PLC
27 June 2024
27 June 2024
PureTech Health
plc
PDMR
Notifications
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage
biotherapeutics company dedicated to giving life to new classes of
medicine to change the lives of patients with devastating
diseases, announces the sale of certain shares by members of executive management
and non-executive directors ("PDMRs") pursuant to its recently
completed Tender Offer.
The Company's total issued ordinary
share capital is 257,927,489 shares, 18,608,909 shares of which are
held in treasury by the Company.
PDMR Notification
The information contained in the below notification is
disclosed in accordance with Article 19 of the EU Market Abuse
Regulation.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Eric Elenko
John LaMattina
Robert Langer
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Eric Elenko: President
John LaMattina: Non-Executive
Director
Robert Langer: Non-Executive
Director
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
PureTech Health plc
|
|
b)
|
LEI
|
213800LVPDNO2Z9T9I39
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
|
Ordinary Shares of PureTech Health plc
ISIN GB00BY2Z0H74
|
|
|
|
b)
|
Nature of the transaction
|
Sale of ordinary shares pursuant to Company's recently
completed Tender Offer.
|
|
c)
|
Price(s) and volume(s)
|
|
Individual
|
Price
|
Volume
|
|
Eric Elenko
|
2.50
GBP
|
479,553
ordinary shares
|
|
John LaMattina
|
2.50
GBP
|
54,882
ordinary shares
|
|
Robert Langer
|
2.50
GBP
|
233,098
ordinary shares
|
|
|
e)
|
Date of the transaction
|
24 June 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
About PureTech Health
PureTech is a clinical-stage
biotherapeutics company dedicated to giving life to new classes of
medicine to change the lives of patients with devastating diseases.
The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders that is being
advanced both internally and through its Founded Entities.
PureTech's R&D engine has resulted in the development of 29
therapeutics and therapeutic candidates, including two that have
received both U.S. FDA clearance and European marketing
authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech
or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All
of the underlying programs and platforms that resulted in this
pipeline of therapeutic candidates were initially identified or
discovered and then advanced by the PureTech team through key
validation points.
For more information,
visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHXDLFLZQLEBBL
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
